Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Precision NanoSystems and Alnylam Pharmaceuticals have entered into an agreement for discovering and developing new lipid nanoparticles, known as small lipid nanoparticles (sLNPs), using microfluidics technology.
Subscribe to our email newsletter
Based on their small particle size of approximately 20 nanometers, sLNPs have the potential for broadened biodistribution beyond liver delivery.
Alnylam chief scientific officer Kenneth Koblan said they look forward to working with Precision NanoSystems to support research efforts around the discovery of novel sLNPs that they believe have the potential to improve and broaden biodistribution.
NanoSystems CEO James Taylor said they are excited to have formed this exclusive collaboration with Alnylam focused on the discovery and development of novel sLNPs using microfluidics technology.